EVALUATION OF MINIMAL RESIDUAL DISEASE IN HIGH-RISK CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA USING AN IMMUNOLOGICAL APPROACH DURING COMPLETE REMISSION

被引:0
|
作者
CONSOLINI, R
SCAMARDELLA, F
LEGITIMO, A
PUTTI, C
GRANCHI, D
PAOLUCCI, P
LIPPI, A
GUAZZELLI, C
ACQUAVIVA, A
ROSANDA, C
BASSO, G
MACCHIA, P
机构
[1] UNIV PADUA, DIPARTIMENTO PEDIAT, I-35100 PADUA, ITALY
[2] UNIV BOLOGNA, PEDIAT CLIN 3, I-40126 BOLOGNA, ITALY
[3] UNIV FLORENCE, PEDIAT CLIN, I-50121 FLORENCE, ITALY
[4] UNIV SIENA, IST CLIN PEDIAT, I-53100 SIENA, ITALY
[5] IST GIOVANNA GASLINI, GENOA, ITALY
关键词
MINIMAL RESIDUAL DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; COMPLETE REMISSION;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Sensitive methods for detecting residual disease may complement conventional morphology while monitoring the response to treatment in leukemia patients. Methods. We studied minimal residual disease (MRD) by selecting via a colony assay a peripheral blood (PB) cell population enriched in putative malignant cells and detecting occult leukemic cells by double immunologic analysis performed on colonyforming cells (CFC). Using this combined technique we assayed the PB of high risk children with acute lymphoblastic leukemia (ALL) in order to demonstrate possible differences in <<the residual tumor cell burden>> among leukemia patients and to correlate these with a 3-year clinical follow-up. Results. In all 22 patients positive results were obtained for up to 18 months following induction chemotherapy at times of apparent hematologic remission. Common ALL (cALL) patients exhibited a mean of 9.6% cAlla+ cells (range: 2% to 30%), whereas cALL antigen (cALLA) and cALLA/Tdt or CDla/Tdt combination were never found in the colonies derived from healthy individuals. Six out of 22 cALL patients expressed a mean of 16.5% cALLA+/Tdt+ CFC (range: 2% to 35%). Five TALL children presented a mean of 24% CD1a/Tdt+ cells (range: 8% to 44%). Extensive follow-up indicates a correlation between the percentage of CFC Tdt+/lymphoid marker+ cells (more than 10%) and subsequent clinical relapse. In one patient relapse occurred after 16 months with a dramatic increase in the number of leukemic cells. In contrast, the decline in malignant cells, observed in two cases, predicted a favourable course. Five patients tested before autologous bone marrow transplantation (ABMT) presented high number of positive cells and relapsed at various times. Conclusions. We conclude that this approach to the study of MRD could be valuable in monitoring the efficacy of chemotherapy, as well in evaluating the quality of purged marrow.
引用
收藏
页码:297 / 305
页数:9
相关论文
共 50 条
  • [1] MINIMAL RESIDUAL DISEASE IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA
    CARR, T
    STEVENS, RF
    LANCET, 1994, 343 (8891): : 190 - 190
  • [2] MINIMAL RESIDUAL DISEASE IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA - ANALYSIS OF PATIENTS IN CONTINUOUS COMPLETE REMISSION OR WITH CONSECUTIVE RELAPSE
    BIONDI, A
    YOKOTA, S
    HANSENHAGGE, TE
    ROSSI, V
    GIUDICI, G
    MAGLIA, O
    BASSO, G
    TELL, C
    MASERA, G
    BARTRAM, CR
    LEUKEMIA, 1992, 6 (04) : 282 - 288
  • [3] THE SIGNIFICANCE OF DETECTION OF MINIMAL RESIDUAL DISEASE IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA
    POTTER, MN
    STEWARD, CG
    OAKHILL, A
    BRITISH JOURNAL OF HAEMATOLOGY, 1993, 83 (03) : 412 - 418
  • [4] POSSIBILITIES AND LIMITATIONS OF IMMUNOLOGICAL MARKER ANALYSES FOR THE DETECTION OF MINIMAL RESIDUAL DISEASE IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA
    LUDWIG, WD
    VANDONGEN, JJM
    THIEL, E
    TEICHMANN, JV
    HOFMANN, J
    RIEHM, H
    ONKOLOGIE, 1990, 13 (03): : 166 - 174
  • [5] TREATMENT OF CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA WITH HIGH-RISK OF RELAPSE
    JANKASCHAUB, GE
    WINKLER, K
    KIRSTEIN, Z
    HOBEL, U
    GRAUBNER, U
    GUTIAR, P
    HAAS, RJ
    JURGENS, H
    SPAAR, HJ
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 1991, 36 (10): : 3 - 7
  • [6] RESULTS OF TREATMENT OF HIGH-RISK CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA
    KENDE, G
    ELNAJJAR, K
    BENBASSAT, I
    NEUMAN, Y
    BALLIN, A
    RAMOT, B
    MEDICAL AND PEDIATRIC ONCOLOGY, 1983, 11 (01): : 49 - 52
  • [7] THE DETECTION OF MINIMAL RESIDUAL DISEASE IN ACUTE LYMPHOBLASTIC-LEUKEMIA
    POTTER, MN
    BLOOD REVIEWS, 1992, 6 (02) : 68 - 82
  • [8] DETECTION OF MINIMAL RESIDUAL DISEASE IN ACUTE LYMPHOBLASTIC-LEUKEMIA
    ROBERTS, WM
    ESTROV, Z
    ZIPF, TF
    BLOOD, 1995, 86 (03) : 1237 - 1238
  • [9] THE STUDY OF MINIMAL RESIDUAL DISEASE IN ACUTE LYMPHOBLASTIC-LEUKEMIA
    KNECHTLI, CJC
    GOULDEN, NJ
    LANGLANDS, K
    POTTER, MN
    JOURNAL OF CLINICAL PATHOLOGY-CLINICAL MOLECULAR PATHOLOGY EDITION, 1995, 48 (02): : M65 - M73
  • [10] THE USE OF DNA PROBES TO MONITOR MINIMAL RESIDUAL DISEASE IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA
    KATZ, F
    BALL, L
    GIBBONS, B
    CHESSELLS, J
    BRITISH JOURNAL OF HAEMATOLOGY, 1989, 73 (02) : 173 - 180